In the past 52-week period, shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) have moved within the range of $0.13 to $5.68. On the stock’s most recent trading day, the company’s shares ended the regular session at $0.20, which is 96.48% higher than its 52-week high.
Argos Therapeutics, Inc. (ARGS) has demonstrated a 20-day simple moving average (SMA) of 19.49%, and a 50-day SMA of 14.22%. This public company’s current market capitalization stands at $17.99 million.Analyzing Consensus Estimates, Sales Revenue and Net Income
When considering entering a position, it is crucial to understand the average enthusiasm level expressed by Wall Street analysts for that particular stock. According to the latest data, the consensus recommendation for Argos Therapeutics, Inc. (ARGS) is Hold.
Publicly-traded organizations typically post revenue and earnings results that fall either above or below the average Wall Street estimate. In the most recent quarterly financial report, for the quarter ending Sep. 2017, Argos Therapeutics, Inc. (ARGS) delivered a 46.50% surprise with its net revenue.
Meanwhile, during the same quarter Argos Therapeutics, Inc. (ARGS) delivered a -35.00% earnings surprise. Net earnings for the quarter were posted at -$0.13 per share, whereas Wall Street had forecast -$0.20 per share.Ownership at Argos Therapeutics, Inc. (ARGS), According to Most Recent SEC Filings
We can find critical insight by examining institutional ownership, which are reported in public companies’ most recent 13F filings. Argos Therapeutics, Inc. (ARGS) has 0 billion shares outstanding currently, 18.44% of which belong to institutional investors.
Additionally, according to the most recent 13F filing from Argos Therapeutics, Inc. (ARGS), there were 6 new positions totaling 1,022,441 shares of the company’s stock. There were 13 sold out positions, on the other hand, totaling 539,909 shares.Short, Medium and Long Term Indicators
A stock’s average trade volume, as recorder over the short, medium and long terms, is helpful to analyze in order to gain a better understanding of trading activity and investor sentiment. Argos Therapeutics, Inc. (ARGS) has had a 20-day average volume of 7,810,625 shares, with an average of 20% of short term indicators pointed at Buy.
The stock’s 50-day average volume has been 5,767,678 shares, with an average of 50% of medium term indicators pointing toward Buy. Finally, its 100-day average volume is 4,157,430 shares with 67% of long-term indicators pointing to Sell.